Aurobindo gets USFDA nod for Tofacitinib tablets

5 Jun 2026via Indian Pharma PostSource

English हिंदी తెలుగు தமிழ்ಕನ್ನಡ मराठी বাংলা ગુજરાતી

Aurobindo gets USFDA nod for Tofacitinib tablets — Aurobindo Pharma has received final approval from the USFDA for its generic Tofacitinib tablets, used to treat rheumatoid arthritis. The approval allows the company to launch the product immediately, expanding its footprint in the US market. This positions Aurobindo to capture a share of the $1.2 billion annual market.

📊 STOCKS: AUROPHARMA | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #USFDA

#USFDA#generic#approval

Stocks mentioned

AUROPHARMAAurobindo Pharma Limited

⚠️ This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.

Trade smarter on NSE

Live option chains, FII flows, PCR, AI analysis — for NIFTY, BANKNIFTY & 200+ F&O stocks.

Start for ₹1 →